Ablaze Pharma Charts Path for GPC3-Targeted Polypeptide with RayzeBio Partnership
Ablaze Pharma, a Chinese biopharmaceutical company, has announced its development plan for a GPC3-targeted polypeptide...
Fosun Pharmaceutical Gets NMPA Approval for FCN-159 Phase II Study in LCH
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that it has...
Shanghai Fosun Pharma Commences Phase III Trial for HER2-Targeted FS-1502
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a prominent Chinese pharmaceutical company,...
Kangtai Bio Partners with AstraZeneca and Combiphar to Expand Vaccine Collaboration
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading Chinese vaccine manufacturer, has entered...
CStone Pharmaceuticals’ Sugemalimab Study Published in JCO for R/R ENKTL Treatment
CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, announced that the Journal of Clinical Oncology...
IceCure Medical Gains NMPA Approval for Cryoablation Technology in China
Israel-based IceCure Medical (NASDAQ: ICCM) has announced that it has obtained regulatory approval from China’s...
SciNeuro Pharmaceuticals and Secarna Pharmaceuticals Ink CNS Disease Research Deal
China-based SciNeuro Pharmaceuticals and Germany’s Secarna Pharmaceuticals GmbH & Co. KG have announced a research...
Beijing’s QL Bio Secures Tens of Millions in Funding for Proteomics Platform Upgrade
QL Bio, a Beijing-based proteomics testing company, has reportedly secured tens of millions of renminbi...
ImmVira’s MVR-C5252 Receives NMPA Approval for Glioma Treatment Development
China-based biotechnology company ImmVira has received approval from the National Medical Products Administration (NMPA) for...
Round 8 VBP Tender Results Announced with RMB 21.6 Billion Market
The National Allied Procurement Office has issued an initial notification upon the completion of Round...
Harbour BioMed Reports 846.5% YOY Revenue Increase and Expands R&D in 2022 Financials
Global biotechnology company Harbour BioMed (HKG: 2142), with operations in the United States, the Netherlands,...
Janssen to Halt RSV Adult Vaccine Development, Impacting Phase III Trial
Johnson & Johnson (J&J; NYSE: JNJ) subsidiary, Janssen, has announced its decision to terminate its...
Luye Pharma Group Reports 15% Revenue Growth in 2022 Financial Results
China-based Luye Pharma Group (HKG: 2186) has released its 2022 financial report, recording a total...
Pfizer’s Ritlecitinib Heads for Priority Review in China for Vitiligo Treatment
The China’s Center for Drug Evaluation (CDE) website has indicated that Pfizer’s (NYSE: PFE) ritlecitinib,...
Boston Scientific Partners with Scivita Medtech for Disposable Electronic Cholangioscope
Boston Scientific Corporation (NYSE: BSX), a leading figure in the medical device industry, has announced...
Transcenta’s Osemitamab Receives FDA Orphan Drug Designation for Pancreatic Cancer
China-based biotechnology company Transcenta Holdings Ltd (HKG: 6628) has announced that its drug TST001 (osemitamab),...
CNBG Partners with China CDC to Strengthen Disease Prevention and Public Health
China National Biotec Group Company Limited (CNBG) has announced a significant long-term partnership with the...
ImmuneOnco Achieves Full Enrollment in Phase II Study of IMM01 for CMML
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has announced the successful completion of patient enrollment in its...
Shanghai Bio-Heart Begins RADIUS-HTN Study for Iberis RDN System in France
China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced the first patient enrollment...
Shenzhen Hepalink’s OncoVent Secures Licensing Deal with Orient EuroPharma for Oregovomab
Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced that its subsidiary, OncoVent, has...